WHI-P180 – 1 mg

Brand:
Cayman
CAS:
211555-08-7
Storage:
-20
UN-No:
Non-Hazardous - /

WHI-P180 is a multi-kinase inhibitor with IC50 values of 4.5 and 66 nM for the human proto-oncogene RET and kinase insert domain receptor (KDR), respectively.{40380} It also inhibits EGFR (IC50 = 4 μM) and binds to tau-tubulin kinase 1 (TTBK1; Kds = 0.46 and 0.24 μM for phosphorylated and non-phosphorylated TTBK1, respectively).{40381,40382} WHI-P180 inhibits JAK3 and JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts.{40381,40383} WHI-P180 (25 mg/kg, i.p) inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis.{40384}  

 

Available on backorder

SKU: 23452 - 1 mg Category:

Description

A multi-kinase inhibitor (IC50s = 4.5 and 66 nM for human recombinant RET and KDR, respectively); inhibits EGFR (IC50 = 4 μM); binds to TTBK1 (Kds = 0.46 and 0.24 μM for phosphorylated and non-phosphorylated TTBK1, respectively); inhibits JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts; inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis


Formal name: 3-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol

Synonyms:  Janex 3

Molecular weight: 297.3

CAS: 211555-08-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|Growth Factor Receptors||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Allergy